Pharma channel feed

No­var­tis makes it of­fi­cial: Al­con is mov­ing its HQ from Texas to Gene­va ahead of a spin­off

7 years ago

Acor­da shares crater af­ter ap­peals court dash­es re­main­ing hopes for sal­vaging Ampyra patents — gener­ics loom

7 years ago

The Broad wins an­oth­er — per­haps fi­nal — bat­tle in the war over Feng Zhang's CRISPR patents

7 years ago
People

Am­i­cus chief John Crow­ley is snubbed at the FDA on his lat­est pitch for quick drug re­view. He'll be back, but an­a­lyst sees big de­lay

7 years ago

Re­volv­ing door be­tween in­dus­try and FDA con­tin­ues to spin

7 years ago
People

The pain won't stop. GSK ends the week with a slap­down on its Nu­cala ap­pli­ca­tion for COPD

7 years ago

GSK’s flop Poti­ga is picked up and head­ed for a quick makeover for pe­di­atric epilep­sy. Any bets on the prospec­tive price?

7 years ago

As­traZeneca, Am­gen roll up a 'break­through' at the FDA in hot pur­suit of a po­ten­tial game chang­er in asth­ma

7 years ago

Ham­mered hard by a sur­pris­ing FDA re­jec­tion, Io­n­is spin­out Akcea of­fers an ex­pla­na­tion and then chops 1-in-10 staffers

7 years ago
R&D

GSK chops 650 jobs, vow­ing to shift more mon­ey to a weak R&D ef­fort

7 years ago

In a rare de­lay for the fast PD-1/L1 crowd, FDA tells Roche to wait on its Tecen­triq/Avastin triple for lung can­cer

7 years ago

Li­cens­ing As­traZeneca castoff, Bio­haven preps PhI­II ef­fort in new neu­rode­gen­er­a­tive in­di­ca­tion

7 years ago
R&D

FDA waves Loxo through for sec­ond 'break­through' in tis­sue-ag­nos­tic can­cer ther­a­py

7 years ago

Chi-Med, Eli Lil­ly score a land­mark ap­proval in Chi­na for the first new can­cer drug de­vel­oped in Chi­na

7 years ago
China

Once a block­buster-to-be, Te­va fi­nal­ly sounds taps for its PhI­II los­er laquin­i­mod

7 years ago
R&D

Sanofi reaps first fruit of Abl­ynx buy­out with a Eu­ro­pean OK for its lead rare dis­ease drug

7 years ago

An­oth­er Shkre­li-like drug price con­tro­ver­sy? Lea­di­ant finds it­self in the spot­light af­ter 500-fold price hike — FT

7 years ago

Strug­gling MannKind sees shares rock­et up on $105M-plus al­liance with Unit­ed on in­haled tre­pros­tinil

7 years ago

The high-roller club in bio­phar­ma: Who’s pay­ing top-dol­lar for up­fronts? And who are the busiest play­ers at the deal ta­ble?

7 years ago
R&D

Look­ing to re­tain its run­ner-up po­si­tion in HIV, Mer­ck scores two new ap­provals for HIV ther­a­pies

7 years ago

Bay­er gets green light to sell long-act­ing he­mo­phil­ia A ther­a­py as Roche mus­cles in with Hem­li­bra

7 years ago

FDA launch­es pi­lot pro­gram in sup­port of com­plex tri­al de­signs for drugs and bi­o­log­ics

7 years ago

Pop­u­lar biotech boost­ers get­ting mul­ti­mil­lion-dol­lar pay­outs on Wall Street as top an­a­lysts are wooed with big of­fers — WSJ

7 years ago

Pfiz­er bris­tles at 'mis­lead­ing' com­ments from Big Phar­ma ri­vals Am­gen, Genen­tech on biosim­i­lars

7 years ago
First page Previous page 292293294295296297298 Next page Last page
A service from the Financial Times